All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL
Cancer · 01.06.2026 · 132 (11)
DOI: 10.1002/cncr.70403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 01.06.2026. Verfasst von Leah Lawrence. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, phase 3 AMPLIFY trial results show significantly improved progression‐free survival in comparison with standard chemoimmunotherapy for adults with chronic or small lymphocytic leukemia. In addition, a study adds new evidence on use of salvage focal therapy for radio‐recurrent prostate cancer, and stereotactic radiation is linked to fewer symptoms in patients with 5–20 brain metastases.
Zitieren
APA
Lawrence, L. (2026). All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL. Cancer, 132(11). https://doi.org/10.1002/cncr.70403
Vancouver
Lawrence L. All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL. Cancer. 2026;132(11). doi:10.1002/cncr.70403
BibTeX
@article{Lawrence2026,
author = {Lawrence, Leah},
title = {All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL},
journal = {Cancer},
year = {2026},
volume = {132},
number = {11},
doi = {10.1002/cncr.70403}
}
EUVIMED